US 11,746,152 B2
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
Stephen S. Yoo, Centreville, VA (US); Mien-Chie Hung, Houston, TX (US); Chia-Wei Li, Houston, TX (US); and Seung-Oe Lim, Houston, TX (US)
Assigned to STCUBE, INC., Seoul (KR); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Appl. No. 16/318,840
Filed by STCUBE, INC., Seoul (KR); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Jul. 19, 2017, PCT No. PCT/US2017/042797
§ 371(c)(1), (2) Date Jan. 18, 2019,
PCT Pub. No. WO2018/017673, PCT Pub. Date Jan. 25, 2018.
Claims priority of provisional application 62/364,441, filed on Jul. 20, 2016.
Prior Publication US 2019/0218297 A1, Jul. 18, 2019
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/44 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/44 (2013.01); A61K 2039/507 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A method of reducing or slowing growth of a PD-L1-positive tumor in a subject in need thereof, comprising administering to a subject having a PD-L1 positive tumor a combination of effective amounts of a first and a second isolated antibody, wherein said first antibody selectively binds to glycosylated PD-L1; and wherein said second antibody selectively binds to glycosylated PD-L1,
wherein the first isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 4, a CDR H2 with an amino acid sequence of SEQ ID NO: 6, and a CDR H3 with an amino acid sequence of SEQ ID NO:8, or a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 5, a CDR H2 with an amino acid sequence of SEQ ID NO: 7, and a CDR H3 with an amino acid sequence of SEQ ID NO: 9 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 12, a CDR L2 with an amino acid sequence of SEQ ID NO: 14, and a CDR L3 with an amino acid sequence of SEQ ID NO: 16 and
wherein the second isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 45, a CDR H2 with an amino acid sequence of SEQ ID NO: 47, and a CDR H3 with an amino acid sequence of SEQ ID NO: 49, or a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 46, a CDR H2 with an amino acid sequence of SEQ ID NO: 48, and a CDR H3 with an amino acid sequence of SEQ ID NO: 50 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 53, a CDR L2 with an amino acid sequence of SEQ ID NO: 55, and a CDR L3 with an amino acid sequence of SEQ ID NO: 57 or
wherein the second isolated antibody has a VH domain comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 61, a CDR H2 with an amino acid sequence of SEQ ID NO: 63, and a CDR H3 with an amino acid sequence of SEQ ID NO: 65 or a VH comprising a CDR H1 with an amino acid sequence of SEQ ID NO: 62, a CDR H2 with an amino acid sequence of SEQ ID NO: 64, and a CDR H3 with an amino acid sequence of SEQ ID NO: 66 and a VL domain comprising a CDR L1 with an amino acid sequence of SEQ ID NO: 69, a CDR L2 with an amino acid sequence of SEQ ID NO: 71, and a CDR L3 with an amino acid sequence of SEQ ID NO: 73.